CASCAID Study: Cytisine as a smoking cessation aid

Phase 3

Completed

• Conditions: Smoking Cessation; Public Health - Epidemiology

• Registration Number: ACTRN12610000590066
• Lead Sponsor: Health Research Council NZ

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-07-21
• Study Completion: 2013-08-20
• Last Update Posted: 29 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 1310

Inclusion Criteria

1. they want to stop smoking,
2. they are at least 18 years of age,
3. they are able to provide verbal consent,
4. they have access to a telephone.

Exclusion Criteria

1. they are pregnant or breastfeeding,
2. they are current users of NRT products,
3. they are current users of non-NRT smoking cessation therapies (e.g. buproprion [Zyban], clonidine, nortriptyline, or varenicline [Champix]),
4. they are enrolled in another smoking cessation programme (e.g. Txt2Quit but concurrent referral to a face-to-face provider from Quitline is acceptable) or other cessation study (e.g. Fit2Quit),
5. they have had a heart attack, stroke, or severe angina within the previous two weeks,
6. they have uncontrolled high blood pressure (> 150 mmHg systolic, > 100 mmHg diastolic),
7. they have phaeochromocytoma,
8. they suffer from schizophrenia.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The proportion of participants that have been continuously abstinent at one month (self report of smoking not more than five cigarettes after the Quit date).[2 months post quit day]